Log in
NYSEAMERICAN:NAVB

Navidea Biopharmaceuticals Stock Forecast, Price & News

$2.49
+0.08 (+3.32 %)
(As of 10/28/2020 12:00 AM ET)
Add
Compare
Today's Range
$2.36
Now: $2.49
$2.53
50-Day Range N/A
52-Week Range
$0.63
Now: $2.49
$5.36
Volume61,368 shs
Average Volume694,276 shs
Market Capitalization$65.53 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The company operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages; and NAV4694, a fluorine-18 labeled positron emission tomography imaging agent for use as an aid in the imaging and evaluation of patients with signs or symptoms of Alzheimers disease and mild cognitive impairment. It is also developing NAV5001, an iodine-123 labeled single photon emission computed tomography imaging agent that is used as an aid in the diagnosis of Parkinson's disease and other movement disorders with potential use as a diagnostic aid in dementia; diagnostic substances, including technetium 99m tilmanocept and other diagnostic applications of its Manocept platform; and therapeutic development programs, such as therapeutic applications of its Manocept platform, as well as various development programs. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was founded in 1983 and is headquartered in Dublin, Ohio.
Read More
Navidea Biopharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.84 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Biotechnology
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNYSEAMERICAN:NAVB
Previous SymbolNYSEMKT:NAVB
CUSIP63937X10
Phone+1-614-7937500
Employees14

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Market Cap$65.53 million
Next Earnings Date11/5/2020 (Estimated)
OptionableOptionable
$2.49
+0.08 (+3.32 %)
(As of 10/28/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive NAVB News and Ratings via Email

Sign-up to receive the latest news and ratings for NAVB and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of Navidea Biopharmaceuticals?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Navidea Biopharmaceuticals in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Navidea Biopharmaceuticals
.

When is Navidea Biopharmaceuticals' next earnings date?

Navidea Biopharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for Navidea Biopharmaceuticals
.

How were Navidea Biopharmaceuticals' earnings last quarter?

Navidea Biopharmaceuticals Inc (NYSEAMERICAN:NAVB) issued its earnings results on Thursday, August, 13th. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.12) by $0.01. The biopharmaceutical company had revenue of $0.27 million for the quarter, compared to analysts' expectations of $0.60 million.
View Navidea Biopharmaceuticals' earnings history
.

What price target have analysts set for NAVB?

2 analysts have issued 12 month price objectives for Navidea Biopharmaceuticals' stock. Their forecasts range from $7.00 to $8.00. On average, they expect Navidea Biopharmaceuticals' stock price to reach $7.50 in the next year. This suggests a possible upside of 201.2% from the stock's current price.
View analysts' price targets for Navidea Biopharmaceuticals
.

Are investors shorting Navidea Biopharmaceuticals?

Navidea Biopharmaceuticals saw a decline in short interest in the month of September. As of September 15th, there was short interest totaling 197,500 shares, a decline of 12.6% from the August 31st total of 226,100 shares. Based on an average trading volume of 355,900 shares, the short-interest ratio is presently 0.6 days. Approximately 1.1% of the company's stock are short sold.
View Navidea Biopharmaceuticals' Short Interest
.

Who are some of Navidea Biopharmaceuticals' key competitors?

What other stocks do shareholders of Navidea Biopharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Navidea Biopharmaceuticals investors own include Opko Health (OPK), Ampio Pharmaceuticals (AMPE), CorMedix (CRMD), Catalyst Pharmaceuticals (CPRX), FuelCell Energy (FCEL), Palatin Technologies (PTN), Trevena (TRVN), Agenus (AGEN), Dynavax Technologies (DVAX) and Genocea Biosciences (GNCA).

Who are Navidea Biopharmaceuticals' key executives?

Navidea Biopharmaceuticals' management team includes the following people:
  • Mr. Jed A. Latkin, CEO, COO, CFO, Sec., Treasurer & Director (Age 45)
  • Dr. Michael Stanley Rosol Ph.D., Chief Medical Officer
  • Erika Gibson, Director of Fin. & Admin.
  • Mr. William J. Regan, Chief Compliance Officer (Age 67)
  • Ms. Sharon Correia, Sr. Director of Corp. Communications

What is Navidea Biopharmaceuticals' stock symbol?

Navidea Biopharmaceuticals trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "NAVB."

How do I buy shares of Navidea Biopharmaceuticals?

Shares of NAVB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Navidea Biopharmaceuticals' stock price today?

One share of NAVB stock can currently be purchased for approximately $2.49.

How big of a company is Navidea Biopharmaceuticals?

Navidea Biopharmaceuticals has a market capitalization of $65.53 million. Navidea Biopharmaceuticals employs 14 workers across the globe.

What is Navidea Biopharmaceuticals' official website?

The official website for Navidea Biopharmaceuticals is www.navidea.com.

How can I contact Navidea Biopharmaceuticals?

Navidea Biopharmaceuticals' mailing address is 4995 Bradenton Ave Ste 240, DUBLIN, OH 43017-3552, United States. The biopharmaceutical company can be reached via phone at +1-614-7937500.

This page was last updated on 10/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.